Dividend Distribution - The company plans to distribute a cash dividend of 1.00 CNY per 10 shares, totaling 43,065,000.00 CNY, which represents 19.19% of the net profit attributable to ordinary shareholders for the year [6]. - In the first half of 2024, the company distributed a cash dividend of 2.00 CNY per 10 shares, amounting to 86,130,000.00 CNY, accounting for 38.38% of the net profit attributable to ordinary shareholders [6]. - The total cash dividend for 2024 is projected to be 3.00 CNY per 10 shares, totaling 129,195,000.00 CNY, which constitutes 57.57% of the net profit attributable to ordinary shareholders [6]. - The company has maintained a focus on balancing long-term development and shareholder returns in its profit distribution policy [161]. - The company has not made any adjustments to its profit distribution policy during the reporting period [160]. Financial Performance - The company's operating revenue for 2024 was CNY 5,431,591,346.96, representing a 6.80% increase compared to CNY 5,085,696,347.20 in 2023 [23]. - The net profit attributable to shareholders for 2024 decreased by 20.69% to CNY 224,399,100.35 from CNY 282,952,031.26 in 2023 [23]. - The net cash flow from operating activities for 2024 was CNY 347,242,212.03, a decline of 54.90% compared to CNY 770,018,562.27 in 2023 [23]. - The basic earnings per share for 2024 was CNY 0.52, down 20.00% from CNY 0.65 in 2023 [24]. - The company achieved a weighted average return on equity of 6.09% in 2024, a decrease of 2.05 percentage points from 8.14% in 2023 [24]. Operational Efficiency - The production capacity utilization rate increased by 7.6 percentage points year-on-year, demonstrating improved operational efficiency [32]. - The company has a production capacity of 70,000 tons/year for glyphosate, making it one of the top four producers in China [39]. - The company has established a comprehensive risk prevention mechanism to enhance internal control effectiveness [33]. - The company has established a comprehensive governance structure and management system, enhancing operational efficiency [40]. Research and Development - The company applied for a record 63 patents during the year, indicating strong innovation efforts [32]. - The company is actively engaged in research on green and efficient pesticide processes and new flame retardants [32]. - The company invested a total of RMB 207.06 million in R&D, with 11 new projects initiated and 17 projects currently under research [85]. - The company completed 11 R&D projects in 2024, with 6 projects carried over to 2025 for continued development, including 17 high-end pesticide formulations approved for sale [85]. - The company is focusing on green and fine chemical technologies, achieving breakthroughs in continuous processes for hazardous operations like chlorination and nitration [86]. Environmental Protection - The company invested 1,341 million CNY in environmental protection during the reporting period [175]. - The company implemented over 30 environmental improvement projects, enhancing its waste treatment capabilities and significantly reducing pollutant discharge intensity [176]. - The company maintained a "green" dynamic environmental credit rating throughout the reporting period [176]. - The company’s subsidiaries reported stable pollutant discharge levels, meeting environmental standards with effective monitoring systems in place [177]. - The company’s overall environmental compliance is reflected in its adherence to the specified discharge limits for various pollutants [182]. Market Performance - The overseas sales revenue increased by over 30% year-on-year, reflecting effective marketing strategies [32]. - The company’s sales revenue for amide herbicides has been steadily increasing, with product quality leading in the domestic market [78]. - The global chemical crop protection market reached $74.806 billion in 2023, with a year-on-year growth of 0.1% [77]. - The global crop protection pesticide market is expected to reach $70.061 billion in 2024, a decrease of 6.4% compared to 2023, with the total pesticide market size at $77.195 billion, down 6.82% year-on-year [108]. Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and management team to ensure clear responsibilities and independent operations [125]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements [126]. - The company has not faced any penalties from securities regulatory agencies in the past three years [141]. - The company has no significant discrepancies in governance compared to regulatory requirements, ensuring compliance with laws and regulations [128]. Human Resources - The company employed a total of 2,721 staff, with 1,682 in the parent company and 1,039 in major subsidiaries [154]. - The workforce includes 1,694 production personnel, 196 sales personnel, and 624 technical personnel [154]. - The company has established a standardized training system, linking training assessment results directly to employee job grading and promotion [157]. - The company introduced 22 key personnel through a market-oriented compensation mechanism during the reporting period [156]. Strategic Initiatives - The company plans to enhance its investment in R&D for genetically modified herbicides following recent policy changes in the agricultural sector [73]. - The company is positioned to benefit from the "Implementation Plan for the Innovation and Development of the Fine Chemical Industry" which supports mergers and acquisitions [74]. - The company plans to implement mergers and acquisitions to strengthen its core competitiveness and achieve high-quality development [113]. - The company aims to establish a technology barrier through new product and technology breakthroughs, promoting long-term development [86].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,745,960,034.77, representing a 10.15% increase compared to CNY 1,585,034,690.16 in the same period last year[4]. - Net profit attributable to shareholders increased by 89.10% to CNY 155,506,106.27 from CNY 82,236,390.36 year-on-year[4]. - The net profit after deducting non-recurring gains and losses rose by 88.29% to CNY 150,424,728.03 compared to CNY 79,890,658.15 in the previous year[4]. - Basic and diluted earnings per share increased by 89.47% to CNY 0.36 from CNY 0.19 in the same period last year[4]. - The weighted average return on equity improved by 1.84 percentage points to 4.10% from 2.26% year-on-year[4]. - Total revenue for Q1 2025 reached ¥1,745,960,034.77, an increase of 10.1% compared to ¥1,585,034,690.16 in Q1 2024[15]. - Net profit for Q1 2025 was ¥155,566,359.06, a significant increase of 83.1% compared to ¥84,985,087.54 in Q1 2024[16]. - Operating profit for Q1 2025 was ¥196,151,955.71, compared to ¥108,036,941.63 in Q1 2024, indicating a growth of 81.6%[16]. - The total comprehensive income attributable to the parent company was 153,275,316.53 RMB in the current period, compared to 82,353,024.64 RMB in the previous period, reflecting a year-over-year increase of approximately 86.1%[17]. - The company reported a total comprehensive income of 153,335,569.32 RMB for the current period, compared to 85,101,721.82 RMB for the previous period, indicating a strong performance improvement[17]. Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -144,447,379.10, worsening by 111.25% compared to CNY -68,378,030.19 in the previous year[4]. - In Q1 2025, the company reported a net cash flow from operating activities of -144,447,379.10 RMB, compared to -68,378,030.19 RMB in Q1 2024, indicating a decline in operational cash flow[19]. - The company incurred total cash outflows from operating activities of 1,400,451,300.13 RMB in Q1 2025, slightly lower than 1,404,008,632.58 RMB in Q1 2024[20]. - The net cash flow from investing activities was -296,564,375.11 RMB in Q1 2025, compared to -171,726,834.48 RMB in Q1 2024, indicating increased investment expenditures[20]. - Cash flow from financing activities showed a significant increase, with a net inflow of 366,787,349.55 RMB in Q1 2025, compared to 23,878,873.62 RMB in Q1 2024[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,580,495,758.08, a slight decrease of 0.62% from CNY 8,633,606,390.28 at the end of the previous year[5]. - The company's total assets decreased to ¥8,580,495,758.08 from ¥8,633,606,390.28, a decline of 0.6%[12]. - Total liabilities decreased to ¥4,471,018,819.02 from ¥4,698,794,462.01, a reduction of 4.8%[13]. - The company's equity increased to ¥4,109,476,939.06 from ¥3,934,811,928.27, reflecting a growth of 4.4%[13]. - Shareholder equity attributable to the parent company increased by 4.12% to CNY 3,871,574,020.25 from CNY 3,718,441,923.98[5]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 21,841, with the largest shareholder holding 28.96% of the shares[8]. Research and Development - Research and development expenses for Q1 2025 were ¥49,625,232.21, slightly down from ¥49,970,406.04 in Q1 2024[16]. Other Income - The company reported non-recurring gains of CNY 5,081,378.24, primarily from government subsidies and other income[6]. - The company received tax refunds amounting to 51,059,429.46 RMB in Q1 2025, significantly higher than 14,072,381.92 RMB in Q1 2024[20]. - The company reported a financial income of ¥4,101,740.61 in Q1 2025, compared to ¥556,082.06 in Q1 2024, showing a substantial increase[16].

KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 关于南通江山农药化工股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况的专项说明 毕马威华振专字第 2502900 号 南通江山农药化工股份有限公司董事会： 我们接受委托，按照中国注册会计师审计准则审计了南通江山农药化工股份有限公司 (以 下简称"江山股份") 2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负 债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司 ...

南通江山农药化工股份有限公司 关于会计师事务所2024年度履职情况的评估报告 南通江山农药化工股份有限公司（以下简称"公司"）聘请毕马威华振会计师 事务所（特殊普通合伙）（以下简称"毕马威华振"） 作为公司 2024 年度年报审 计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事 务所管理办法》，公司对毕马威华振在2024 年审计中的履职情况进行了评估。经评 估，公司认为，2024 年度毕马威华振资质等方面合规有效，履职能够保持独立性， 勤勉尽责，公允表达意见。具体情况如下： 一、资质条件 毕马威华振会计师事务所于1992年8月18日在北京成立，于2012年7月5日获财政 部批准转制为特殊普通合伙的合伙制企业，更名为毕马威华振会计师事务所（特殊 普通合伙），2012年7月10日取得工商营业执照，并于2012年8月1日正式运营。 毕马威华振总所位于北京，注册地址为北京市东城区东长安街1号东方广场东2 座办公楼8层。 毕马威华振的首席合伙人邹俊，中国国籍，具有中国注册会计师资格。 截至2024年12月31日，毕马威华振有合伙人241人，注册会计师1,309人，其中签 署过证券服务业务审计报告 ...

证券代码：600389 证券简称：江山股份 公告编号：临 2025-021 南通江山农药化工股份有限公司 2024 年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号行业信息披露：第十三 号—化工》、《关于做好主板上市公司 2024 年年度报告披露工作的重要提醒》的 要求，南通江山农药化工股份有限公司（以下简称"公司"）现将 2024 年度主要 经营数据披露如下： 注 1：上述产量含自用量、农药按含量折原药计算（下同）。 注 2：除草剂产品包括草甘膦、酰胺类等产品；杀虫剂产品包括敌百虫、敌敌畏等产品； 氯碱产品包括烧碱、盐酸、液氯、次氯酸钠等产品，其中烧碱产销量按 32%、48% 烧碱实物量计算（下同）。 注 3：阻燃剂（磷系）产品包含 TCPP、BDP 产品（下同）。 本报告之经营数据未经审计，公司董事会提醒投资者审慎使用上述数据。 特此公告。 南通江山农药化工股份有限公司董事会 2025 年 4 月 22 日 2 杀虫剂产品 27,071.74 27,1 ...

南通江山农药化工股份有限公司 董事会审计委员会 2024 年度履职情况报告 根据中国证监会《上市公司治理准则》《上市公司独立董事管理办法》、上 海证券交易所《上市公司自律监管指引第1号——规范运作》以及公司《董事会 审计委员会工作细则》等规定，公司董事会审计委员会本着勤勉尽责的原则，认 真履行职责，切实有效地监督了公司的外部审计，认真审核公司财务信息披露的 真实、准确和完整性；指导公司内部审计工作，督促公司内部审计制度的建立健 全及有效实施；严格审查公司重大关联交易等。现将公司审计委员会2024年度工 作情况报告如下： 一、审计委员会基本情况 公司第九届董事会审计委员会委员为：独立董事方国兵、张利军、周献慧、 董事顾建国、陈云光，主任委员为方国兵。审计委员会全体成员均具有能够胜任 审计委员会工作职责的专业知识和商业经验，审计委员会的构成符合监管要求及 《公司章程》等相关文件的规定。 二、审计委员会 2024 年度会议召开情况 报告期内审计委员会共召开了 7 次会议，全体委员均出席会议，并对议案投 了赞成票，具体召开情况如下： | 时间 | | | 会议名称 | 审议内容 | | --- | --- | --- ...

南通江山农药化工股份有限公司 2024 年度社会责任报告 公司董事会共由9名董事组成，其中包括3名独立董事，分别是行业、会计、 法律方面的专家，在各自领域均具有丰富的经验与能力。公司董事会下设四个专 门委员会，包括战略委员会、审计委员会、薪酬与考核委员会、提名委员会。其 中审计委员会、薪酬与考核委员会、提名委员会主任委员均由独立董事担任，且 独立董事人数超过半数，公司设立了独立董事专门会议机制，报告期内公司共召 开全部由独立董事参加的专门会议4次，对公司关联交易等事项进行了事前审议， 充分发挥了独立董事的专业指导和监督作用，保护了中小股东的合法权益。 前 言 南通江山农药化工股份有限公司（以下简称"江山股份"） 位于南通市经 济技术开发区江山路 998 号，股票代码 600389。公司主要从事农药、阻燃剂、 氯碱等化工产品的生产和销售。 江山股份下设多家子公司，其中南通江山新能科技有限公司主要从事热电联 产和氯碱制造；南通南沈植保科技开发有限公司主要从事农药制剂和助剂生产； 哈尔滨利民农化技术有限公司主要从事农药制剂生产；南通联膦化工有限公司以 生产水处理专用化学品为主；江山（宜昌）作物科技有限公司主要生产绿 ...

南通江山农药化工股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会计政策变更是南通江山农药化工股份有限公司（以下简称"公司"） 根据中华人民共和国财政部（以下简称"财政部"）相关规定进行的变 更，本次会计政策变更对公司损益、总资产和净资产无重大影响。 证券代码：600389 证券简称：江山股份 公告编号：临 2025—024 一、概述 2023 年 10 月 25 日财政部发布的《企业会计准则解释第 17 号》(财会 [2023] 21 号) (以下简称"解释第 17 号") 中规定了"关于流动负债与非流动负债的划 分"。财政部 2024 年 12 月 06 日发布的《企业会计准则解释第 18 号》(财会 [2024] 24 号) (以下简称"解释第 18 号") 中规定了"关于不属于单项履约义务的保证 类质量保证的会计处理"。公司依据财政部上述规定对相关会计政策进行变更。 2025 年 4 月 20 日，公司分别召开第九届董事会第十八次会议及第九届监事 会第十八次会议 ...

公司代码：600389 公司简称：江山股份 南通江山农药化工股份有限公司 2024年度内部控制评价报告 南通江山农药化工股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变 ...

证券代码：600389 证券简称：江山股份 公告编号：临 2025-027 南通江山农药化工股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 南通江山农药化工股份有限公司（以下简称"公司"）已于 2025 年 4 月 22 日发布公司 2024 年年度报告及 2025 年第一季度报告，为便于广大投资者更全面 深入地了解公司 2024 年度及 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 5 月 12 日（星期一）14:00-15:00 举行 2024 年度暨 2025 年第一季度业绩 说明会，就投资者关心的问题进行交流。 一、 说明会类型 1 会议召开时间：2025 年 5 月 12 日(星期一) 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 30 日(星期 ...